Show simple item record

dc.contributor.authorGiovannoni, G
dc.contributor.authorMarta, M
dc.contributor.authorDavis, A
dc.contributor.authorTurner, B
dc.contributor.authorGnanapavan, S
dc.contributor.authorSchmierer, K
dc.date.accessioned2016-09-05T11:15:12Z
dc.date.issued2016-04-25
dc.date.issued2016-10
dc.date.issued2016-10
dc.date.submitted2016-05-10T19:15:01.314Z
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/14950
dc.description.abstractThere are several options for switching people with multiple sclerosis (MS) who are at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some of these have risks that need to be managed, for example, the risks of carrying over asymptomatic PML from natalizumab on to the new therapy, and the risk of rebound disease activity associated with a prolonged washout after starting natalizumab. We propose a pragmatic bridging strategy, using another disease-modifying therapy (DMT), to reduce the risk of switching from natalizumab to alemtuzumab. We also discuss the caveats and subtleties associated with sequencing DMTs in MS and the complex decision making involved.
dc.format.extent389 - 393
dc.languageENG
dc.language.isoenen_US
dc.subjectAlemtuzumab
dc.subjectMULTIPLE SCLEROSIS
dc.subjectNatalizumab
dc.subjectPML
dc.subjectprogressive multifocal leukoencephalopathy
dc.titleSwitching patients at high risk of PML from natalizumab to another disease-modifying therapy.
dc.typeJournal Article
dc.rights.holder© 2016, British Medical Journal Publishing Group
dc.identifier.doi10.1136/practneurol-2015-001355
dc.relation.isPartOfPract Neurol
dc.relation.isPartOfPract Neurol
dc.relation.isPartOfPract Neurol
pubs.author-urlhttp://www.ncbi.nlm.nih.gov/pubmed/27114560
pubs.issue5
pubs.organisational-group/Queen Mary University of London
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute
pubs.organisational-group/Queen Mary University of London/Faculty of Medicine & Dentistry/Blizard Institute/Neuroscience and Trauma
pubs.publication-statusPublished
pubs.volume16


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Return to top